Ideaya Biosciences announced that it intends to offer and sell up to $150M of shares of its common stock in an underwritten public offering. J.P. Morgan, Jefferies and Citigroup are acting as joint book-running managers for the offering.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IDYA:
- Ideaya Biosciences price target raised to $35 from $30 at Wedbush
- Ideaya Biosciences price target raised to $30 from $26 at Oppenheimer
- Ideaya Biosciences price target raised to $40 from $32 at Guggenheim
- Ideaya Biosciences upgraded to Buy from Hold at Stifel
- Ideaya announces interim Phase 2 data for darovasertib, crizotinib combination
